Gelonghui, July 4?$Hansoh Pharmaceutical Group (03692.HK) $According to the announcement, the piperazeli capsule developed by Jiangsu Hausen Pharmaceutical Group Co., Ltd., a subsidiary of the company, has won the drug registration certificate issued by the State Drug Administration of China.

This product is an antineoplastic drug and is suitable for locally advanced or metastatic breast cancer with positive hormone receptor (HR) and negative human epidermal growth factor receptor 2 (HER2). It should be used in combination with aromatase inhibitors as the initial endocrine therapy in postmenopausal women.

Obtaining the drug registration certificate for this product will further enrich and improve the group's product portfolio.